BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

By WebmasterMarch 24, 2015November 1st, 2024No Comments

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine
Read more here

Previous PostHealthQx First to Receive New Certification by HCI3
Next PostMelior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostHealthQx First to Receive New Certification by HCI3

Next PostMelior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes